Silverarc Capital Management LLC Purchases Shares of 100,000 Viridian Therapeutics, Inc. (NASDAQ:VRDN)

Silverarc Capital Management LLC purchased a new stake in Viridian Therapeutics, Inc. (NASDAQ:VRDN - Free Report) in the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund purchased 100,000 shares of the company's stock, valued at approximately $1,917,000. Silverarc Capital Management LLC owned 0.13% of Viridian Therapeutics as of its most recent filing with the Securities and Exchange Commission (SEC).

Other hedge funds and other institutional investors also recently bought and sold shares of the company. Diadema Partners LP bought a new stake in Viridian Therapeutics during the 4th quarter valued at $948,000. Eversept Partners LP increased its stake in shares of Viridian Therapeutics by 12.8% during the fourth quarter. Eversept Partners LP now owns 779,998 shares of the company's stock valued at $14,953,000 after buying an additional 88,766 shares during the period. J. Safra Sarasin Holding AG bought a new stake in shares of Viridian Therapeutics in the fourth quarter valued at about $699,000. Tower Research Capital LLC TRC lifted its stake in Viridian Therapeutics by 824.3% in the fourth quarter. Tower Research Capital LLC TRC now owns 34,172 shares of the company's stock worth $655,000 after acquiring an additional 30,475 shares during the period. Finally, MetLife Investment Management LLC grew its holdings in Viridian Therapeutics by 21.8% during the 4th quarter. MetLife Investment Management LLC now owns 44,295 shares of the company's stock worth $849,000 after acquiring an additional 7,914 shares in the last quarter.

Analysts Set New Price Targets

Several equities research analysts have recently commented on the stock. HC Wainwright restated a "buy" rating and issued a $34.00 price target on shares of Viridian Therapeutics in a report on Wednesday. Needham & Company LLC reissued a "buy" rating and set a $38.00 price objective on shares of Viridian Therapeutics in a report on Tuesday, January 7th. Three investment analysts have rated the stock with a hold rating and nine have given a buy rating to the company. Based on data from MarketBeat, the stock has a consensus rating of "Moderate Buy" and an average target price of $35.70.

Viridian Therapeutics Stock Down 0.4 %

VRDN traded down $0.06 during trading on Friday, hitting $13.50. The stock had a trading volume of 524,676 shares, compared to its average volume of 1,200,464. The stock has a 50 day simple moving average of $14.24 and a two-hundred day simple moving average of $18.27. The company has a debt-to-equity ratio of 0.04, a quick ratio of 18.55 and a current ratio of 18.55. Viridian Therapeutics, Inc. has a twelve month low of $9.90 and a twelve month high of $27.20. The company has a market capitalization of $1.10 billion, a PE ratio of -3.13 and a beta of 0.81.

Viridian Therapeutics (NASDAQ:VRDN - Get Free Report) last posted its quarterly earnings data on Thursday, February 27th. The company reported ($0.81) earnings per share for the quarter, topping analysts' consensus estimates of ($1.05) by $0.24. Viridian Therapeutics had a negative return on equity of 70.12% and a negative net margin of 85,127.16%. The firm had revenue of $0.07 million during the quarter, compared to analysts' expectations of $0.05 million. On average, research analysts predict that Viridian Therapeutics, Inc. will post -4.03 earnings per share for the current year.

Viridian Therapeutics Profile

Viridian Therapeutics, Inc, a biotechnology company, discover and develops treatments for serious and rare diseases. The company's product pipeline includes VRDN-001, a monoclonal antibody targeting insulin-like growth factor-1 receptor that is in Phase 3 clinical trial for the treatment of thyroid eye disease (TED); and VRDN-003, a next generation IGF-1R humanized monoclonal antibodies targeting IGF-1R and incorporating half-life extension technology for the treatment of TED.